AngioGenex, Inc. is engaged in the discovery and development of drugs that target regulators of gene transcription. The Company’s lead clinical candidate, Idantirx/AGX51, lowers the concentration of Id -inhibitor of differentiation proteins in cancer cells. The Id genes and proteins are not normally present in adult tissues unless pathologic conditions such as cancer are present. AngioGenex has developed a diagnostic test to quantitate Id proteins in blood and expects to use...